Effect of febuxostat on serum uric acid and renal function in patients with hyperuricemia. -open label, active (allopurinol)-controlled clinical study-

Effect of febuxostat on serum uric acid and renal function in patients with hyperuricemia. -open label, active (allopurinol)-controlled clinical study- - Effect of febuxostat on serum uric acid and renal function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008727

Enrollment

100

Registered

2012-09-01

Start date

2012-07-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Allopurino50-100mg Febuxostat10-20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with hyperuricemia and renal dysfunction (2)Patients who treated with allopurinol, and their levels of serum uric acid are more than 6.0mg/dl (3)eGFR<60ml/min/1.73m2

Exclusion criteria

Exclusion criteria: (1)Febuxostat sensitivity (2)Hemodialysis patients (3)Secondary hyperuricemia (4)SBP>=160 or DBP>=100 (5)AST and ALT levels less than 2-times the upper limit of normal (6)Newly onset CAD and CVD within 6 months (7)Treated with mercaptopurine and azathioprine (8)During breast-feeding (9)Doctor considers inappropriate as subjects

Design outcomes

Primary

Measure	Time frame
change ratio of serum uric acid eGFR change from baseline	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026